Jeil Pharma Holdings Inc (KRX:002620)

Market Cap	131.41B
Revenue (ttm)	773.03B
Net Income (ttm)	-48.91B
Shares Out	15.35M
EPS (ttm)	-3,158.31
PE Ratio	n/a
Forward PE	n/a
Dividend	50.00 (0.58%)
Ex-Dividend Date	Dec 27, 2024

Volume	16,980
Average Volume	30,553
Open	8,680.00
Previous Close	8,750.00
Day's Range	8,440.00 - 8,950.00
52-Week Range	6,950.00 - 11,070.00
Beta	0.86
RSI	53.23
Earnings Date	Aug 11, 2025

About Jeil Pharma Holdings

Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Employees: 37
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 002620

Financial Performance

In 2024, Jeil Pharma Holdings's revenue was 779.82 billion, a decrease of -3.01% compared to the previous year's 804.04 billion. Losses were -51.16 billion, 214.8% more than in 2023.